NCT06654037View on ClinicalTrials.gov

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

January 12, 2026

Study Completion Date

January 12, 2026

Conditions
Metastatic Microsatellite Stable Colorectal CarcinomaRefractory Microsatellite Stable Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8
Interventions
DRUG

Abemaciclib

Given PO

PROCEDURE

Biopsy Procedure

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Fluorouracil

Given IV

PROCEDURE

Radiologic Imaging Procedure

Undergo radiologic imaging

Trial Locations (8)

10461

RECRUITING

Montefiore Medical Center-Einstein Campus, The Bronx

RECRUITING

Montefiore Medical Center-Weiler Hospital, The Bronx

10467

RECRUITING

Montefiore Medical Center - Moses Campus, The Bronx

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

45069

RECRUITING

University of Cincinnati Cancer Center-West Chester, West Chester

45219

RECRUITING

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati

92612

RECRUITING

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine

92868

RECRUITING

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH